Table 2. Difference in IL-6 concentrations between with tuberculosis patients with and without unfavorable treatment outcomes in the Indian external validation cohort.

Treatment outcomes	Log10 difference in baseline cytokine levels comparing cases to controls
	Unadjusted difference (95%CI)	p-value	Adjusted difference (95%CI)	p-value
All participants
Composite	0.24 (0.16 to 0.32)	<0.001	0.26 (0.17 to 0.36)	<0.001
Failure	0.10 (-0.02 to 0.24)	0.10	0.16 (-0.02 to 0.36)	0.07
Recurrence	0.26 (0.17 to 0.35)	<0.001	0.27 (0.16 to 0.38)	<0.001
Death	0.32 (0.18 to 0.46)	<0.001	0.32 (0.14 to 0.50)	<0.001
Diabetes only
Composite	0.23 (0.12 to 0.35)	<0.001	0.22 (0.07 to 0.37)	0.01
Failure	0.15 (-0.03 to 0.34)	0.11	0.15 (-0.12 to 0.43)	0.27
Recurrence	0.22 (0.10 to 0.36)	0.001	0.25 (0.05 to 0.44)	0.01
Death	0.30 (0.10 to 0.50)	0.004	0.26 (0.01 to 0.51)	0.04

Adjusted analysis account for CXR score including cavitation, smear grade, ever smoking, diabetes and pre-treatment illness duration. Age, sex and BMI are adjusted by study design. Diabetes-restricted analysis are further adjusted for HbA1c levels. CI – confidence interval.